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currently	 recognized	 as	 a	worthwhile	modality	 of	 treatment	 for	 pa-
tients	with	 end-	stage	 lung	diseases.1	More	 than	55	000	 transplants	
have	 been	 performed	worldwide	 over	 the	 last	 three	 decades.	 This	
quantitative	increase	was	concurrent	with	improvements	in	the	physi-
cal	and	mental	aspects	of	health	in	these	patients.1,2	The	survival	rate	
has	 increased	due	to	advances	 in	surgical	 techniques	and	postoper-
ative	care	such	as	guidance	on	lifestyle	and	administration	of	potent	
antimicrobial	agents.	Besides	the	increase	in	life	years,	it	is	important	
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to	 immunosuppression,	 and	 side	 effects	 of	 medications.3,4	 In	 both	
the	short	and	long	term	these	issues	can	also	affect	HRQoL.	Several	
studies	 have	 been	 performed	 with	 health-	outcome	 measurement	
instruments	that	capture	a	specific	element	of	HRQoL.	 In	the	short	
term,	 most	 patients	 are	 found	 to	 experience	 meaningful	 improve-
ments	 after	 lung	 transplantation.5-10	 However,	 the	 generalizability	
of	these	studies	is	constrained	by	methodological	problems	such	as	
cross-	sectional	design,	short-	term	follow-	up,	and	small	sample	sizes.	
A	 few	 longitudinal	 studies	have	evaluated	HRQoL	after	 lung	 trans-
plantation.11-14	The	 biggest	 changes	 they	 report	 occur	 in	 the	 early	
posttransplantation	 period	 in	 the	 domains	 of	 physical	 health	 and	
functioning,	like	walking	capacity,	which	generally	remained	constant	
in	 subsequent	 follow-	ups.	 But	 these	 studies	 have	 methodological	
problems	too:	small	sample	size	and	inclusion	of	combined	heart	and	
lung	 transplant	 patients.	 In	 light	 of	 their	 systematic	 review,	 Seiler	
and	 colleagues	 summarized	HRQoL	 and	 psychological	 outcomes	 in	




cohort	 of	 lung	 transplant	 patients	 demonstrated	 by	 longitudinal	
serial	annual	evaluations	up	to	15	years	after	transplantation.	We	
then	 evaluate	 the	 effect	 of	 demographic	 and	 clinical	 factors	 on	
that	 trend	during	 the	posttransplantation	period.	Our	hypothesis	






Center	Groningen	 (UMCG)	who	gave	 consent	 to	participate	were	
included	 in	 the	 study.	 In	 addition,	 patients	 from	 the	 University	
Medical	 Center	 Utrecht	 (UMCU)	 and	 Erasmus	 Medical	 Center	
Rotterdam	(EMC)	were	included	from	2002	onward.	Inclusion	crite-
ria	were	candidacy	for	lung	transplantation,	age	≥18,	and	sufficient	























Anxiety	 Inventory	 (STAI),	 a	 20-	item	 self-	report	 measure	 in	 which	
responses	 are	 given	 on	 a	 4-	point	 Likert	 scale	 from	 4	 (always)	 to	 1	
(never).	The	overall	score	ranges	from	20	to	80,	with	80	representing	
the	worst	possible	state	of	anxiety.16	Depression	was	measured	with	




























basis	 of	 their	 clinical	 relevance	 and	 similar	 previous	 studies	 for	 the	
purpose	of	 assessing	 their	 effect	on	 the	 trends	of	HRQoL	 found	 in	
this	study.	The	list	consisted	of	gender,	age,	working	situation,	marital	





56	 or	 older).	 Graphs	 were	 drawn	 to	 demonstrate	 the	 trend	 of	 the	
















Chicago,	 IL).	SigmaPlot	version	12.3	 (Systat	Software,	 Inc.,	San	Jose,	
CA)	was	used	for	drawing	the	graphs.
3  | RESULTS
3.1 | Patients’ participation and demographics
From	 1992	 to	 2014	 a	 total	 of	 1083	 patients	 with	 end-	stage	 lung	




a	 lack	of	 interest,	a	short	 time	between	candidacy	and	surgery,	and	
being	too	ill.	Eventually,	370	(34%)	of	those	initial	participants	under-
went	 lung	 transplantation.	 In	addition	 to	 those	828	participants,	56	
patients	(from	the	original	1083	candidates)	filled	in	the	instruments	
after	 transplantation	 for	 the	 first	 time,	bringing	 the	 total	number	of	
participants	up	 to	884	 (81%).	Figure	1	 schematically	depicts	 the	 in-






waiting	 list	 at	 age	 13	 and	 14,	 but	 they	 started	 to	 fill	 in	 the	 instru-
ments	after	they	turned	18.	A	total	of	487	patients	(55%)	were	female	
(Table	1).	 A	 large	 proportion	 of	 the	 participants	 (30%)	 had	 become	
end-	stage	lung-	disease	patients	due	to	chronic	obstructive	pulmonary	
disease	(COPD),	and	a	smaller	share	due	to	cystic	fibrosis	(CF)	(17%).
3.2 | Baseline differences in HRQoL
In	 the	waiting	 list	 assessment,	 female	 patients	 showed	 significantly	
higher	levels	of	anxiety	and	depression	than	male	patients	(Figure	2).	





tion,	 and	 physical	 activity	 (52.34	±	5.3,	 8.90	±	2.3,	 and	 35.74	±	3.1)	








higher	 levels	of	depression	 (56.7	±	0.6)	 than	patients	with	CF,	 alpha	
1-	antitrypsin	 deficiency,	 and	 other	 pulmonary	 diseases	 (52.8	±	0.8,	
53	±	0.8,	and	54.1	±	0.5,	respectively).
3.3 | Patterns of HRQoL after LTx
The	STAI	and	Zung	mean	scores	as	well	as	all	domains	of	the	NHP,	
except	 for	 pain,	 declined	 sharply	 immediately	 after	 transplantation.	
Overall,	 the	 study	 population	 reported	 a	 considerably	 higher	 per-
ceived	 health	 condition	 (VAS	 score)	 compared	 to	 the	 assessment	
when	placed	on	the	waiting	list	(Table	2).	The	improvement	in	HRQoL	
remained	 relatively	 steady	 from	 the	 first	 year	 after	 LTx	 to	 the	 end	
of	follow-	up.	After	transplantation,	most	patients	reported	an	HRQoL	
comparable	to	that	of	the	general	population.21	However,	posttrans-
plantation	 patients	 had	 a	 higher	 level	 of	 depression	 compared	 to	
	values	for	the	general	population	sample	(P < .001).17
3.4 | Patterns of HRQoL after LTx in different groups
GEE	analysis	was	performed	to	evaluate	the	longitudinal	differences	
in	HRQoL	scores	on	select	independent	variables	(Appendices	1	and	







scores	on	sleep	(P = .011)	and	physical	activity	(P = .0001).
From	the	first	to	the	fourth	year	after	transplantation,	the	lowest	
STAI	scores	were	found	among	cystic	fibrosis	patients	and	the	high-
est	 among	 COPD	 patients.	 However,	 GEE	 analysis	 did	 not	 show	 a	
significant	difference	between	these	diagnostic	groups.	A	comparison	
of	 the	4	diagnostic	 groups	 showed	 that	patients	with	CF	and	alpha	
1-	antitrypsin	 deficiency	 had	 significantly	 lower	 levels	 of	 depression	
(P = .003	 and	 P = .025,	 respectively)	 than	 patients	 with	 other	 di-
agnoses.	The	perception	of	overall	 health	was	better	 in	 the	CF	 and	
alpha	 1-	antitrypsin	 groups,	 according	 to	 their	 VAS	 score	 (P = .001 
and P = .016).	CF	patients	also	had	the	lowest	scores	on	energy	level	
(P = .007),	sleep	(P = .001),	and	physical	activity	(P < .001).
The	 STAI	 and	 Zung	mean	 scores	 of	 both	working/studying	 and	
nonworking	groups	decreased	considerably	1	year	after	the	transplan-
tation	and	remained	constant	during	the	posttransplantation	period.	







































1 year after LTx
2 years after LTx
3 years after LTx
4 years after LTx
5 years after LTx
6 years after LTx
7 years after LTx
8 years after LTx
9 years after LTx
11 years after LTx
10 years after LTx
13 years after LTx
12 years after LTx
15 years after LTx
14 years after LTx
End of follow-up
N=56 Post LTx inclusion
N=90 died
N=420 did not receive LTx
N=54 lost to follow-up
N=15 died
N=22 censored
N=17 lost to follow-up
N=18 died
N=11 censored
N=23 lost to follow-up
N=16 died
N=13 censored
N=5 lost to follow-up
N=10 died
N=4 censored
N=5 lost to follow-up
N=9 died
N=8 censored
N=21 lost to follow-up
N=14 died
N=3 censored
N=0 lost to follow-up
N=8 died
N=7 censored
N=6 lost to follow-up
N=12 died
N=6 censored
N=4 lost to follow-up
N=9 died
N=0 censored
N=0 lost to follow-up
N=7 died
N=4 censored
N=0 lost to follow-up
N=5 died
N=7 censored
N=0 lost to follow-up
N=4 died
N=0 censored
N=0 lost to follow-up
N=3 died
N=2 censored
N=0 lost to follow-up
N=8 died
N=2 censored
N=0 lost to follow-up
Percentages in central row represent the proportion of living patients that were not censored
and filled in the instruments.
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The	working/studying	group	had	a	statistically	significant	lower	level	
of	anxiety	(P = .024)	and	depression	(P = .016).	This	group	also	had	bet-
ter	scores	in	the	physical	activity	and	pain	domains	of	NHP	(P < .001),	
especially	in	the	first	6	years	of	the	posttransplantation	period.























lung	 transplant	 recipients	 up	 to	 15	years	 after	 surgery.	 Lung	 trans-
plantation	 is	 performed	 in	 chronic,	 end-	stage	 lung	 disease	 patients	





































F IGURE  2 Reversed mean scores for 
depressive	symptoms	(Zung)	by	gender
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in	view	of	the	improvement	in	lung	function	during	the	posttransplan-
tation	period.	Constant	use	of	immunosuppressive	drugs	after	trans-
plantation,	 as	 well	 as	 the	 risk	 of	 many	 immunosuppression-	related	
health	problems	like	various	cancers	and	infectious	diseases,	but	also	

















Another	 finding	 of	 our	 study	 is	 that	 female	 patients	 generally	
had	 relatively	worse	 HRQoL	 both	 before	 and	 after	 transplantation.	
However,	 both	 genders	 showed	 significant	 improvement	 in	HRQoL	
afterward.	The	worse	HRQoL	 among	 females	was	 predominantly	 in	











N = 828 Year 1 N = 320 Year 5 N = 161 Year 10 N = 54 Year 15 N = 12
STAI ≤37 10 42.1	(11.2) 32.9	(10.8) 33.4	(10.4) 33.4	(10.9) 36.0	(14.0)
Zung ≤33 8-	9 54.5	(9.5) 41.8	(10.9) 43.0	(10.4) 41.8	(10.5) 43.1	(10.6)
NHP	Energy <15 n/a 67.5	(35.6) 14.3	(29.9) 17.4	(31.7) 17.5	(30.9) 29.4	(45.9)
NHP	Pain <15 n/a 8.3	(17.7) 7.4	(18.4) 9.1	(22.5) 16.0	(29.4) 16.4	(30.7)
NHP	Emotional	
reactions
<15 n/a 18.3	(21.4) 6.0	(13.4) 6.8	(14.7) 8.6	(18.4) 11.9	(20.0)
NHP	Sleep <15 n/a 25.4	(29.8) 16.4	(26.4) 15.7	(25.4) 18.7	(29.1) 3.5	(11.0)
NHP	Social	isolation <15 n/a 13.2	(19.5) 3.2	(9.7) 2.9	(9.0)	 4.8	(13.4) 6.1	(10.4)
NHP	Physical	mobility <15 n/a 51.0	(26.5) 11.1	(19.8) 11.1	(18.3) 13.6	(18.2) 10.0	(15.7)
VAS >82 7-	10 43.7	(18.5) 78.5	(16.8) 77.7	(17.4) 77.8	(15.5) 74.7	(21.9)
Range	of	possible	scores:	STAI,	20	to	80;	Zung,	25	to	100;	NHP,	0	to	100;	and	VAS,	0	to	100.
MID,	minimal	important	difference.
F IGURE  3 Reversed mean scores for 
physical	activity	and	energy	domains	of	
HRQoL	(NHP)	by	gender



































activities	 sooner.	Holding	 higher	 expectations	might	 be	 a	 source	 of	
distress	 and	 cause	more	 anxiety	 and	 depressive	 symptoms.	 Further	
research	with	regard	to	the	causal	 relation	between	expectations	of	
















The	 overall	 health	 condition	 of	 patients	who	worked	 or	 studied	
was	better	than	that	of	the	nonworking	group,	both	before	and	after	
transplantation.	 This	 difference	was	 pronounced	 in	 the	 psychologi-










reported	discrepancies	 in	 the	 long-	term	trend	of	HRQoL	among	pa-
tients	 after	 transplantation,	 but	 those	 studies	 followed	 patients	 for	
only	 a	 few	 years	 or	 used	 a	 retrospective	 study	 design.	 Due	 to	 the	





lung	 transplantation	with	 regard	 to	HRQoL.	We	used	2	generic	and	
2	 domain-	specific	 HRQoL	 instruments	 to	 evaluate	 most	 aspects	 of	
the	health	condition	in	our	population.	When	this	study	was	started	
in	1992,	NHP	was	one	of	the	most	well-	known	instruments	to	eval-
uate	 the	 health	 condition	 of	 patients.	Although	 this	 instrument	 has	
been	applied	less	frequently	in	recent	years,	we	decided	to	continue	
using	 it	 for	the	 latest	evaluations	to	ensure	uniformity	 in	the	results	
of	 the	study.	By	using	 these	4	 instruments	we	covered	most	of	 the	
psychological	and	social	as	well	as	some	or	 the	physical	domains	of	
HRQoL,	which	increased	the	reliability	of	the	results.





possible	 bias	 due	 to	 a	 large	 number	 of	missing	 patients.	 First	we	
evaluated	 the	 demographic	 characteristics	 of	 patients	 who	 were	
censored	due	to	the	end	of	the	study,	lost	to	follow-	up,	or	had	died	
and	compared	these	with	a	profile	of	 the	 included	patients.	There	
were	 no	 salient	 differences	 in	 demographics	 between	missed	 pa-
tients	and	ongoing	participants	at	specific	follow-	up	time	points.	We	
















Another	 limitation	of	this	study	is	that	 it	 lacks	a	control	group.	
Having	 one	 would	 have	 enabled	 a	 more	 thorough	 evaluation	 of	
confounding	 variables	 like	 aging	 and	 social	 changes	 during	 the	
follow-	up	period.	A	potential	 limitation	 is	 the	use	of	 conventional	
self-	report	 instruments	 to	 score	 perceived	 HRQoL.	 These	 instru-
ments	may	be	susceptible	 to	so-	called	adaptation	 in	chronically	 ill	
patients.47	Moreover,	NHP	has	limited	ability	to	detect	respiratory-	
related	impacts	on	perceived	HRQoL.	Finally,	in	this	study	we	exam-
ined	 important	baseline	characteristics	 that	can	affect	 the	HRQoL	
of	patients	long	term	after	LTx.	Based	on	the	research	data	we	col-
lected,	we	are	not	in	the	position	to	study	the	relationship	of	these	





lung	 transplant	 patients	 experience	 improvement	 in	 all	 domains	 of	
HRQoL	within	the	first	year	after	transplantation.	Despite	differences	
in	 survival	 and	 posttransplantation	 immunosuppression	 treatment,	
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APPENDIX 1
I N D E P E N D E N T  D E T E R M I N A N T S  O F  L O N G I T U D I N A L  C H A N G E S  I N  S T A I ,  Z U N G ,  A N D  V A S  S C O R E S
STAI Zung VAS
Estimate (SE) P Value Estimate (SE) P Value Estimate (SE) P Value
Gender
Male −2.077	(1.19) .081 −3.149	(1.23) .011 2.409	(1.89) .202





−1.297	(1.70) .445 −3.876	(1.73) .025 6.761	(2.80) .016
COPD 1.110	(1.49) .457 0.688	(1.52) .650 1.128	(2.38) .636
CF −3.071	(1.58) .051 −5.321	(1.78) .003 7.915	(2.40) .001
Age	groups
Young −2.129	(1.61) .186 −2.902	(1.70) .087 3.876	(2.74) .157
Middle-	aged −1.182	(1.67) .479 −2.211	(1.63) .176 0.611	(2.73) .823
Married −0.236	(1.53) .878 −1.071	(1.50) .476 1.455	(2.32) .531
Type	of	immunosuppression
Tacrolimus 0.75	(1.26) .953 2.085	(1.33) .119 0.845	(2.13) .692
Variables	considered	in	the	GEE	models:	gender,	working	situation,	underlying	medical	disease,	age,	marital	status,	and	immunosuppression	after	
LTx.	SE,	standard	error.
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APPENDIX 3
D I F F E R E N C E  I N  M E A N  S C O R E S  O F  P A T I E N T S  T H A T  D R O P P E D  O U T  A N D  R E S P O N D E N T S  O N  T H E  4  H R Q O L 
INSTRUMENTS :  D IFFERENCE  OF  MEAN  (P  VALUE )
2nd year dropouts N = 54 5th year dropouts N = 19 10th year dropouts N = 9 15th year dropouts N = 10
STAI 1.8	(0.30) 5.1	(0.13) 3.2	(0.45) −0.9	(0.83)
Zung 3.5	(0.07) 3.1	(0.31) 5.9	(0.16) 2.8	(0.57)
NHP	Energy 9.5	(0.07) 12.1	(0.20) 28.5	(0.06) 9.3	(0.57)
NHP	Pain 2.5	(0.39) 3.9	(0.44) −2.5	(0.76) −6.1	(0.39)
NHP	Emotional	reactions 2.3	(0.38) 6.6	(0.16) 2.3	(0.70) 5.3	(0.69)
NHP	Sleep −0.3	(0.94) 6.3	(0.37) 13.8	(0.22) 21.5	(0.12)
NHP	Social	isolation 1.3	(0.38) 1.9	(0.62) −2.4	(0.36) 1.0	(0.85)
NHP	Physical	mobility 7.6	(0.06) 9.3	(0.21) 12.0	(0.16) 15.6	(0.15)
VAS −5.7	(0.06) −4.7	(0.33) −6.7	(0.34) −3.7	(0.63)
